OM Stock Recent News

The consensus price target hints at a 71.7% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The consensus price target hints at an 188.6% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced a one-for-fifteen reverse stock split (the “Reverse Stock Split”) of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Thursday, March 20, 2025. The Company's common stock will continue to trade under Outset's existing trading symbol, OM, on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis when the market opens on Thursday, March 20, 2025, with the new CUSIP number 690145206.

Outset Medical (OM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

In 2025, Bitcoin (BTC -1.18%) has over-promised and under-delivered. After reaching $100,000 in December, Bitcoin looked like a no-brainer option to soar in value this year.

SAN JOSE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 45th annual TD Cowen Health Care conference on Tuesday, March 4, 2025, at 2:30 p.m.

Outset Medical, Inc. (NASDAQ:OM ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Jim Mazzola - Head of Investor Relations Leslie Trigg - Chair and CEO Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Outset Medical Fourth Quarter 2024 Earnings Conference Call.

Outset Medical (OM 3.52%), the innovator behind the Tablo Hemodialysis System, reported fourth-quarter earnings on Wednesday, Feb. 19, that topped analysts' consensus expectations on top and bottom lines. Fourth-quarter revenue of $29.5 million exceeded the forecasted $28 million, indicating resilience in revenue growth despite market hurdles.

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.59 per share a year ago.

SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024.